Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Subscribe To Our Newsletter & Stay Updated